Abstract. Pioglitazone is an insulin-sensitizer with a thiazolidinedione structure. It is used to reduce hyperglycemia and is frequently prescribed to type 2 diabetic patients. However, it causes edema as an adverse effect in some patients. Although the mechanism of edema is unclear, it may bring an increased risk of congestive heart failure. We investigated whether pioglitazone correlates with the level of plasma human atrial natriuretic peptide (hANP), a marker for congestive heart failure. We administered 15 mg/day of pioglitazone for 3 months to 49 patients (34 men and 15 women; mean age: 64 ± 12 years) with type 2 diabetes and no history of pretibial edema. Three of the patients complained of pretibial edema during the 3-month period, and their plasma hANP levels were higher than those of the other 46 before and during the treatment. We therefore suspect that pretibial edema appearing after administration of low-doses of pioglitazone coincides with the level of plasma hANP, and that the appearance of pretibial edema may reflect an increase in circulating blood volume induced by pioglitazone.
PIOGLITAZONE with a thiazolidinedione structure is known as an agent to improve insulin resistance, and is commonly used to treat type 2 diabetes [1] . Thiazolidinediones are specific agonists of the nuclear peroxisome proliferator activated receptor-g, which increases transcription of various proteins that regulate glucose metabolism such as insulin receptor [2] and glucose transporter proteins [3] . Thiazolidinediones also improve serum lipid profiles [4] and prevent the development of diet-induced hypertension [5] . Although thiazolidinediones are tolerated well by adults of all ages in clinical study, they can occasionally cause liver injury and edema as side effects [6] . There have been few reports of pioglitazone causing severe hepatic dysfunction, but edema often occurs [7] .
Human atrial natriuretic peptide (hANP) is secreted by the myocardium as a result of an enlargement of the atrium or ventricle. The expansion of circulating blood volume influences an increase of plasma hANP level [8] . Plasma hANP level is also increased in patients with chronic renal failure and heart failure, and is often used as a clinical marker for the severity of these patients.
The mechanism by which drug-induced edema is caused varies, and the reason why only part of the diabetic patients treated with pioglitazone have edema is unclear. Thus, we investigated whether low-dose administration of pioglitazone influences the level of plasma hANP.
Materials and Methods
Forty-nine patients (34 men and 15 women; mean age ± SD: 64 ± 12 years) with type 2 diabetes were treated with 15 mg/day of pioglitazone for 3 months. None of the patients had a history of pretibial edema. Informed consent was obtained from all patients. The clinical and metabolic characteristics, including body weight, body mass index (BMI = body weight (kg)/ height (m) 2 ), aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, g-glutamyltranspeptidase, blood urea nitrogen, creatinine, hANP and HbA1c, were determined at the start and end of this study. Blood samples were obtained in the sitting position. The month before the start of the study, none of the patients changed their medication. Plasma hANP levels were measured with a sensitive immunoradiometric assay [9] .
All data are expressed as mean ± SD. Changes in clinical characteristics were analyzed using Student's paired t test. Differences between the clinical characteristics of patients with and without edema were analyzed with Mann-Whitney's U test by using the statistical computer program StatView (Abacus Concepts, Inc., Berkeley, CA). P values less than 0.05 were considered to be significant.
Results
Changes in clinical characteristics that occurred during the pioglitazone treatment are given in Table 1 . Neither liver injury nor renal dysfunction occurred within 3 months in any patient. HbA1c levels improved from 7.3 ± 0.8% to 6.6 ± 0.8% (p<0.0001). Although body weight and body mass index did not change noticeably, the plasma hANP levels increased from 19.8 ± 16.1 pg/ml to 26.0 ± 19.7 pg/ml (p = 0.0020). There was no difference between the men and women in the levels of plasma hANP neither at the beginning nor at the end of the treatment period.
Pretibial edema was observed in 3 patients during the treatment period, but they have never had any clinical symptom except edema. As shown in Table 2 , these 3 men were relatively old, and had renal insufficiency or liver cirrhosis; however, they apparently did not have congestive heart failure on electrocardiogram and chest roentgenogram. The edema resolved spontaneously in all 3 within one month of stopping the pioglitazone treatment. The relationship between plasma hANP level and pioglitazone-induced pretibial edema is shown in Table 3 . During this study, the plasma hANP levels were higher in the patients who developed pretibial edema than in those who did not.
Discussion
Ogawa et al. reported changes in hANP and BNP levels in patients with type 2 diabetes when treated with pioglitazone [10] . After pioglitazone treatment, hANP and BNP levels were significantly increased in patients with, but not in those without, left ventricular dysfunction. The patients with left ventricular dysfunction should be carefully treated with pioglitazone treatment.
Pretibial edema can occur for many reasons, including congestive heart failure, renal failure, liver cirrhosis, hypoalbuminemia and venous obstruction. The reasons for thiazolidinedione-induced peripheral edema are likely to be multifactorial, and one of them is probably a result of reduction in renal excretion of sodium and alterations in endothelial permeability [11] . Pioglitazone-induced edema does not occur in all patients who take this medicine, but in only about 7% of Japanese [12] . It has been reported that thiazolidinedione therapy is safe and effective for diabetic patients receiving hemodialysis [13] , and the appearance of pioglitazone-induced edema may depend on individual variations even if the patient has chronic renal failure. Some type 2 diabetic patients do not respond to thiazolidinedione and, for unknown reasons, the effectiveness of thiazolidinedione in lowering blood glucose also differs from patient to patient [14] . It may be necessary to select the patients suitable for thiazolidinedione therapy.
Thiazolidinedione-induced edema seems to be doserelated and occurs most frequently when the thiazolidinediones are used in combination with insulin [15] . None of the subjects in the present study were treated with both pioglitazone and insulin, nor more than 15 mg/day of pioglitazone. Three subjects developed pretibial edema during the 3-months of treatment. Interestingly, their plasma hANP levels both at baseline and at the end of the pioglitazone treatment were higher than those in the patients who did not develop pretibial edema. Thus, we suspect that the appearance of pretibial edema after administration of low doses of pioglitazone coincided with the level of plasma hANP. Patients in whom pioglitazone induces pretibial edema might have a greater retention in circulating blood volume from the beginning. Although the mechanism of pioglitazone-induced edema is still unclear, we should be on guard for the pioglitazone-induced edema, especially if the plasma hANP level is high before the pioglitazone treatment is started. 
